CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.

Chen, Jiang; Jiang, Shi; Shao, Huijiang; Li, Bixia; Ji, Tong; Staiculescu, Daniel; He, Jiayan; Zhao, Jie; Cai, Liuxin; Liang, Xiao; Xu, Junjie; Cai, Xiujun

Chen, Jiang; Jiang, Shi; Shao, Huijiang; Li, Bixia; Ji, Tong; Staiculescu, Daniel; He, Jiayan; Zhao, Jie; Cai, Liuxin; Liang, Xiao; Xu, Junjie; Cai, Xiujun.

Afiliação

Chen J; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Jiang S; Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, 310016, China.
Shao H; Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, 310016, China.
Li B; Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, 310016, China.
Ji T; Cancer Center, Zhejiang University, Hangzhou, 310058, China.
Staiculescu D; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02115, USA.
He J; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Zhao J; Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, 310016, China.
Cai L; Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, 310016, China.
Liang X; Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, 310016, China.
Xu J; Cancer Center, Zhejiang University, Hangzhou, 310058, China.
Cai X; Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.

Sci China Life Sci ; 65(10): 1998-2016, 2022 10.

Article em En | MEDLINE | ID: mdl-35380342

Assuntos

Carcinoma Hepatocelular; Neoplasias Hepáticas; Sistemas CRISPR-Cas; Carcinoma Hepatocelular/tratamento farmacológico; Carcinoma Hepatocelular/genética; Carcinoma Hepatocelular/metabolismo; Fatores de Crescimento de Fibroblastos; Humanos; Proteína 1 Associada a ECH Semelhante a Kelch/genética; Proteína 1 Associada a ECH Semelhante a Kelch/metabolismo; Neoplasias Hepáticas/tratamento farmacológico; Neoplasias Hepáticas/genética; Neoplasias Hepáticas/metabolismo; Fator 2 Relacionado a NF-E2/genética; Fator 2 Relacionado a NF-E2/metabolismo; Fator 2 Relacionado a NF-E2/uso terapêutico; Transdução de Sinais; Sorafenibe/farmacologia; Sorafenibe/uso terapêutico

Palavras-chave

CRISPR screen; Kelch-like ECH-associated protein 1 (KEAP1); fibroblast growth factor 21 (FGF21); hepatocellular carcinoma (HCC); nuclear factor (erythroid-derived 2)-like 2 (NRF2)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Sci China Life Sci Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google